Health Care·Pharmaceuticals·$276.4B
Merck & Co. Inc....
EPS
Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+4.53%
Avg Stock Reaction
-2.10%
In the last quarter, Merck reported an EPS of $2.04, slightly exceeding analyst expectations. The company did not provide revenue figures, but the earnings surprise indicates strong performance.
Management Promises & Guidance
Analysts are expecting a challenging quarter with a consensus EPS of -1.47, reflecting potential pressures on profitability. Revenue expectations are set at $15.8 billion, indicating cautious optimism.
Bull Case
If Merck can exceed EPS expectations and show strong revenue growth, it could signal a robust recovery and renewed investor confidence in its product pipeline.
Bear Case
Conversely, if the company reports a larger-than-expected loss and lower revenue, it may raise concerns about its competitive position and future growth prospects.
EPS
-1.47Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
15.8BRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
How does Merck plan to address the anticipated EPS loss of -1.47?
This will be critical in assessing the company's ability to manage costs and maintain profitability.
Q2
What factors are influencing the expected revenue of $15.8 billion?
Understanding the drivers behind revenue expectations will provide insights into market demand and product performance.
Why consensus could be wrong
The Street may be underestimating Merck's ability to rebound from recent challenges, particularly given its strong historical performance in prior quarters.
Supporting Evidence
Merck has consistently surprised on EPS in the past, indicating potential for a positive outcome this quarter.
The company's focus on R&D could lead to unexpected product launches that drive revenue.
Options pricing suggests a significant move, indicating that the market is prepared for volatility.
Key Risk
If Merck's revenue exceeds $16 billion, it could challenge the current negative sentiment and shift investor expectations.
Pre-commit to what would confirm each case.
The market is debating whether Merck can navigate current challenges effectively while maintaining growth in its core products.
Bull Confirmed If
An EPS of -1.30 or better would indicate stronger-than-expected cost management and product performance.
Bear Confirmed If
An EPS worse than -1.60 would raise serious concerns about profitability and market competitiveness.
Implied Move
±4.2%
Historical Avg
±3.7%
The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.
Options are pricing ±3.9% while MRK has averaged ±3.7% over the last 8 prints — setup is roughly in line with history.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Merck beats expectations, history suggests a positive reaction with an average 1-day move of +4.1%, reinforcing confidence in its growth strategy.
In-Line / Cautious
An inline report may lead to muted reactions as investors assess management's commentary and future guidance.
Miss
If the company misses expectations, the average reaction has been a decline of around -0.74%, indicating potential concerns about its future outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERIZON COMMUNICATIO
Apr 27, 2026